Rituximab

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Rituximab
    1. Pharmacist Assessment Report
    2. Rituximab: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Disclaimer

Pharmacist Assessment Report

Rituximab: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Rituximab, so there is currently no new predicted indication. The drug’s 14 recorded uses are listed below, grouped by the type of evidence behind each one.

Quick overview

Item Content
New predicted indications None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug 14
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication Source
leukemia, lymphocytic, chronic, b-cell licence in another country
microscopic polyangiitis licence in another country
non-hodgkin lymphoma licence in another country
pemphigus licence in another country
rheumatoid arthritis licence in another country
wegener granulomatosis licence in another country
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
acute lymphoblastic/lymphocytic leukemia
b-cell neoplasm
langerhans cell histiocytosis
lymphoma
lymphoma, non-hodgkin, familial
lymphosarcoma
mantle cell lymphoma
richter syndrome

Australia Market Information

Licence Product Dosage form Status
13082M Riximyo Solution for I.V. infusion 100 mg in 10 Valid

Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy / immunotherapy (anti-CD20 monoclonal antibody), not a conventional cytotoxic
Myelosuppression Risk Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification Please refer to the Product Information (PI) warnings and precautions
Monitoring Items Please refer to the PI; the literature compiled also notes viral reactivation risks (for example hepatitis C replication and hepatic flares, PMID 22919406)
Handling Protection Please refer to the PI and local institutional policy

Safety Considerations

Label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Drug Interactions: 90 interactions were identified in the interaction database, with the following examples:

  • Major: adalimumab, baricitinib, deferiprone, samarium (153Sm) lexidronam
  • Moderate: alemtuzumab, azathioprine, anakinra, alefacept, palifermin, roflumilast, zidovudine, chloramphenicol, strontium chloride Sr-89, and several vaccines (tetanus toxoid, anthrax)
  • Minor: zinc salts (sulfate, acetate, gluconate, chloride)

Many of the major and moderate interactions involve additive immunosuppression. Vaccine interactions deserve attention given rituximab’s B-cell depleting effect.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.